Introduction
The discovery of phosphoinositide 3-kinases( PI3Ks) dates back to 1985 when,w ith the seminalw ork of Cantley et al., [1] the specific lipid kinases able to phosphorylate the alcoholic group selectively at the 3-position of phosphatidylinositols were reported.T hree subfamilies of PI3Ks have been identified so far, referredt oa sc lasses I, II, and III. Class Iist he most studied and comprises four isoforms, PI3Ka,P I3Kb,P I3Kd,a nd PI3Kg,t hat share somes tructural features but that are distinct for protein domains, regulatory subunits, and activation mechanism. [2] All class IP I3Ks can catalyze the in vivo conversion of phosphatidylinositol 4,5-bisphosphate (1,P IP2) into phosphatidylinositol 3, 4, PIP3) (Figure 1 ). PIP3 production induces the recruitment to the plasma membrane of 3-phosphoinositide-dependent protein kinase-1(PDK1), which in turn activates protein kinase B( Akt) through phosphorylation on Thr308.
Thirty years of basic research on PI3Ks have unequivocally demonstrated their involvement in ap lethora of biological processes such as cell growth, proliferation, differentiation, and motility. [3] Furthermore,h yperactivation of the PI3K/Akt signaling pathway has been linked to different pathologies, such as cancer and autoimmune diseases. [4, 5] Studies performed with the use of animal models and PI3K inhibitors have established PI3Ka and PI3Kb as promising targets for the treatment of human cancer. [6] Concurrently, the central role of PI3Kg and PI3Kd in leukocyte biology sustains their inhibition as apromising therapeutic approach in av ariety of inflammatory diseases. [5] These findings have prompted both academia andi ndustry research to develop inhibitors targeting all PI3K isoforms. Most of these molecules act by antagonizingt he binding of ATPt ot he PI3K catalytic pocket. To date,h undreds of panand tens of isoform-selective PI3K inhibitors have been discovered, and some of them are in clinicale valuation for tumor treatment ( Figure 2) . [6] [7] [8] These efforts culminated in 2014 with the FDA approvalofi delalisib (8) , aPI3Kd-selective inhibitor for the treatment of patients with relapsed follicularB -cell nonHodgkinl ymphoma or relapsed small lymphocytic lymphoma (SLL). [9] Activation of the phosphoinositide 3-kinase (PI3K) pathway is a key signaling event in cancer,i nflammation, and other proliferative diseases. PI3K inhibitors are already approved for some specific clinical indications, but their systemico n-target toxicity limits their larger use. In particular,w hereas toxicity is tolerable in acute treatment of life-threatening diseases, this is less acceptable in chronic conditions. In the past, the strategy to overcomet his drawback was to block selected isoformsm ainly expressedi nl eukocytes, but redundancy within the PI3K family members challenges the effectiveness of this approach. On the other hand, decreasing exposure to selected target cells represents as o-far unexplored alternative to circumvent systemic toxicity. In this manuscript, we describe the generation of al ibrary of triazolylquinolonesa nd the development of the first prodrug pan-PI3K inhibitor.
Amore accurate analysisoft he structure of already-reported PI3K inhibitors [10] highlighted the lack of molecules displaying ac arboxylic acid group that we here report to be fundamental for binding to the PI3 kinase structural motif. Furthermore,t his functional group can undergo chemical modifications with the intent to develop useful prodrugs. Indeed, this approach might circumvent nonspecific targeting and avoid systemic side effects associated with the use of ap an-PI3K inhibitor,e specially if proposed for topical use. Therefore, in the present manuscript we report the discovery of 37,apotent pan-PI3K inhibitord isplaying as trategic and pivotal carboxylic acid group, which can be esterified to providep rodrugs. The synthesis of 37 and the metabolic stabilityo fi ts prodrugs, along with their full biological characterization, are discussed herein.
Results and Discussion
Chemistry Design, synthesis, and enzyme inhibition On the basis of the considerations discussed above, we decided to start our project by modifyingc ompound LY294002 (9, Figure 3 ), one of the first pan-PI3K inhibitors discovered. [11] This quercetin analogue competesw ith ATPi nt he ATP-binding site of PI3Ks, with an IC 50 value of~0.5 mm against all of the isoforms. The X-ray structure of 9 bound to PI3Kg is also available, [12] and it shows that the morpholino ring partially overlaps the volume occupied by the adenine in the ATP-enzyme complex ( Figure 3 ).
Ah ydrogen bond is formed between the morpholino oxygen atom and the backbonea mide group of residue Val882 of the hinge region, and this bond mimics the interaction that ATPestablishes with the enzyme. There is also aputative hydrogen bond between Lys833 and the carbonyl group. The phenylr ing is located in ap ocket, usually occupiedb yt he ribose of ATP, formedb yM et804 and Trp812 on one side and Met953 on the other,a nd it protrudes toward the solvent-accessible part of the binding pocket. Interestingly, 9 does not extendi nto the phosphate-binding region.
We therefore reasoned that the phenyl ring could be replacedw ith a1 ,4-disubstituted 1,2,3-triazole by ac lick-chemistry approach. [13] In this case, the heterocycle ring would behavea samere linker,d elivering an extra site R( Figure4), that might establisha dditional interactions with the close amino-acid residues, either enhancing the potencyo f9 or impartings electivity.I ndeed, it is important to highlight that the rim of the binding site of class IP I3Ks is the regiono ft he enzymef or which there is major variability in the amino-acid composition amonga ll the four isoforms, [14] andt herefore, it is more amenable to be targeted in the search for selectivity. Owing to the versatility and functional-group tolerance of the Fokin-Sharpless reaction, [15] ac ombinatorial approachw as ex- ploited that would allow exploration of av ast array of different functional groups in the Rp ortion ( Figure 4 ). It is importantt o highlight that modificationo ft he phenylr ing of 9 wasa lready attempted and described. For example, TGX155 (11) , in which the phenylr ing is replaced with a4 -fluoro-2-methylphenoxy moiety,w as shown to be as elective, potent inhibitoro ft he b isoformo fP I3K and ap otential therapeutic agent for cardiovasculard iseases. [16] This example corroborates our hypothesis to replace the phenylr ing of 9.I no ur specific case, we opted to diversify the chemical nature of the Rg roup by exploiting different azides 13.T he azides were preferred as decorating groups rather than alkynes because their chemicalp reparation, startingf rom commerciallya vailable amines, is easier than the more challenging synthesis of alkynes.
Once the goal was fixed, we proceeded with the synthesis of the pivotala lkyne.T he preparationo f12 startedw ith the reactionb etween Meldrum's acid (14)a nd CS 2 (15). The intermediate was then methylated in situ to give 16. [17] Subsequently,t his compound underwent af irst nucleophilic displacementw ith 2-iodoaniline (17)a tr eflux to give 18,w hich was then treated with morpholine (19) i nT HF at reflux to give the second nucleophilic substitution to lead to compound 20. Heatingc ompound 20 in diphenyl ether at 170 8Ct riggered intramolecular aromatic nucleophilic substitution followed by a decarboxylation reaction to afford iodo intermediate 21.S onogashira coupling with trimethylsilyl acetylene gave 22 and subsequent deprotection under basic conditions afforded desired alkyne 12 (Scheme 1).
Once alkyne 12 was obtained, ac ombinatorial parallel synthesis with 30 azides was performed. To this point, before startingt he construction of the library,apreliminary modelr eaction with phenyla zide (23)w as attempted, which revealed that under the standard conditions of the Fokin-Sharpless click reaction( CuSO 4 ·5H 2 O, sodium ascorbate, tBuOH/H 2 O) unexpected compound 24 was obtained insteado fd esired triazole 25.I tw as reasonable to suppose that coppert riggered intramolecular cyclization between the N1 atom and the triple bond, with the formation of a6 -oxopyrrolquinolinicr ing (Scheme 2). [18] In light of this event,w er easoned that in the presence of an already-chelated copper ion, this transformation might be suppressed. The ligand tris[ (1-benzyl-1H-1,2,3-triazol-4-yl) methyl]amine (TBTA, also known as the Chan ligand) was our first choice. It was previously shown that TBTAw as indeed able to stabilizet he oxidation state of the copper(I) ion by encapsulatingi ti ni ts structure and preventing other interactions. [19] The use of the Chan ligand wass uccessful, and under optimized reaction conditions (THF/H 2 O, Cu(OAc) 2 , sodium ascorbate,T BTA), desired 1,2,3-triazole 25 was obtained in excellent yield (Scheme 2).
With this procedurei nh and, we proceeded with our combinatorial strategy.T he azidesw ere selected to introduce both electron-donating and electron-withdrawing groups, hydrogen-bond donors and acceptors, and ionizable functions. They were already presenti no ur databaseo rp repared according to standard procedures. The feasibilityo ft his approachw as demonstrated by precipitation of the resultantp roducts,w hich were purified by filtration and subsequent water/diethyl ether washes. Thisp rocedure resulted in the formation of 30 compounds,w hich were submitted to MS and 1 HNMR spectroscopy analysis to verify their purity (> 95 %) and structural identity. Then, the 1,2,3-triazolesw ere evaluated for their ability to inhibit PI3K isoformso fc lass Ia tafixed concentration of 1 mm, as shown in Table 1 . The synthesized 1,2,3-triazoles along with their ability to inhibitP I3K isoformsa t1mm concentration are Compd RP I3K isoform abgd
[a] PI3K inhibitiond etermined at 1 mm with at least triplicate determinations in multiple experiments; ' + ' refers to those compounds able to inhibit PI3K isoform activity by more than 50 %. Figure 5 ), demonstrating its selectivity over class Iisoforms.
These multiple experiments highlight the pivotal role playedb yt he carboxylic acid if positioned in the meta position on the benzyl ring in increasing the potencyo f this class of compounds. Therefore, startingf rom 37,w ed ecided to replace the 3-methylbenzoic acid group with three linear aliphatic carboxylic acids, namely,p ropionic acid, butyric acid, and pentanoic acid (i.e.,t ogive compounds 55, 56,a nd 57,r espectively), and the carboxyl moiety with its canonical bioisosteres such as sulfonamide (i.e.,c ompound 58); primary (i.e., compound 59), secondary (i.e.,c ompounds 60 and 61), and tertiary( i.e.,c ompound 62)a mides;a nd finally tetrazole( i.e., compound 63). All the attempted substitutions were detrimental to inhibition activity (Table 3) .
We then proceeded to evaluate the ATPc ompetitive inhibitory nature of 37 through an enzymatick inetic study by using an in vitro assay to measuret he PI3Kd activity at various concentrations of ATPa nd 37.A ss howni nF igure 6, LineweaverBurk plot analysis revealed that 37 acts as an ATP-competitive inhibitorf or PI3Kd,a st he plots (straight lines) intersect on the 1/v axis (v = rate of ADP production).
To investigate the binding of 37 in the enzyme active site, the crystal structure of 37 bound to the murine d isoform of PI3K was resolved (see the Supporting Information for technical details). Compound 37 binds in the ATPb inding site in a canonical mode (Figure 7 ), as described for other type Ik inase inhibitors. In detail, the morpholine ring establishes at ypical hydrogen bond with Val882 in the hinge region, analogously to 9;t he quinolone ring is in ac entral pocket with an orientation very similart ot hat of 9 (Figure 7a ), and the carbonyl group is involved in ap utative hydrogen-bonding interaction with Asp911.T he 1,2,3-triazole appears as fundamental to orientate the carboxylic acid group properly.I ndeed, the X-ray structure of 9 showsaperpendicular orientation of the phenyl ring to the central core, whereas 37 is characterized by copla- 
[a] Values are the means of at least threedeterminations in multiple experiments, with 95 %confidence intervals;n.d.:not determined. Figure 5 . Inhibition profile of 37 against a) class Iand b) classes II and III PI3Ks. Each PI3K isoform (30 ng) was incubated with various concentrations of 37 in the presence of ATP (10 mm for PI3Ka,PI3Kb,PI3Kg,PI3Kd,PI3K-C2a,a nd PI3K-C3;100 mm for PI3K-C2g and PI3K-C2b). [20] ATPl oss and consequent ADP production were measured thoughaluminometric assay. The residual PI3K activity after treatmentw ith different concentrations of 37 was calculated as ap ercentageoft he untreated control (recombinant protein + DM-SO). The dose-response curve was obtained by plottingt he PI3K activity [%] versus the logarithmso ft he inhibitorconcentrations. Data are the mean AE SD of at least two independent experiments each performedint riplicate. ChemMedChem 2017 ChemMedChem , 12,1542 ChemMedChem -1554 www.chemmedchem.org 2017 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim nar orientationo ft he 1,2,3-triazole to the quinolinone core. This different spatiald isposition allows for ap ivotal ionic saltbridge interaction between the carboxyl moietya nd Lys708, which is consistentw ith the observed potent inhibitory activity.
Biological assays

Cellular inhibitory activities
After identifying 37 as ap romising candidate, we started to evaluatei ti nc ell-based assays to define its inhibitory activity on the PI3K signaling pathway.T herefore, we selected an in vitro insulin modelt oa ssess the inhibitory effect of 37 in PI3K signaling. NIH3T3c ells were treated with different concentrations of 37,s timulated with insulin, andt he amount of phosphorylated Akt was detected. Nonetheless, as shown in Figure 8 , 37 did not affect the PI3K signaling pathway,a si td id not decrease Akt phosphorylation.
We therefore reasoned that the lack of activity of 37 in cellbased experiments could be ascribed to its inability to cross cell membranes owing to the increased polarity imparted by the ionizedc arboxylic acid. For this reason, we prepared corresponding methyl ester 64.Alipid kinase assay confirmedt hat 64 was not able to inhibit PI3Ka activity at 100 nm (see the Supporting Information), which confirmed the crucial role played by the carboxyl group in the interaction with PI3Ks. Nevertheless, given its hydrophobic nature, it was conceivable that the methyl ester could cross the membrane and, after intracellular enzymatic hydrolysis, explicate its inhibitory activity. To demonstrate that 64 could act as ap rodrug, we treated NIH3T3 cellsw ithd ifferentc oncentration of 64,a nd we then analyzed Akt phosphorylation after insulin stimulation.
As shown in Figure 8 , methyl ester 64 was able to inhibit the PI3K-signalingp athway in ad ose-dependent manner.
To determine whether 64 could inhibitP I3K/Akt in tumor cells, in which the PI3K signaling is hyperactive,P C3 prostatic tumor cells were incubated with different concentrations of 64 ( Figure 9 ). Treatment with 64 attenuated,i nadose-dependent manner,t he levels of p-Akt, as well as the levelso fs ome Akt effectors such us p-PRAS40,p -p70S6K, p-GSK3a/b,a nd p-FOXO3A.
We next determined the effect of 64 on cell proliferation, cell cycle, and apoptosis. As shown in Figure 10 a, 72 hoft reatment with 64 dose-dependently decreased proliferation of PC3 cells. In addition, after 48 ho ft reatment, 64 was able to induce cell-cycle arrest by significantly increasingt he percentage of cells in the G0-G1 phase with concomitantr eduction in the percentage in the Sa nd G2/M phases (Figure 10 b) . On the other hand, 64 did not showa ny effect in inducing cell apoptosis (see the Supporting Information).
Prodrug selectiona nd metabolic stability
The opportunity to generated ifferent prodrugs by acting on the carboxylic acid group stimulatedt he design and synthesis of ap anel of different esterified products. It is important to highlight that by browsing the literature data on PI3K inhibitors it emerged that only one other reported PI3Ka inhibitor displayed ac arboxylic acid, but in this case, the corresponding methyl ester was still ablet oi nhibitt he PI3 kinases and was only four times less active than the corresponding carboxylic acid analogue (IC 50 on PI3Ka:46.0 versus10nm). [21] Twelve esters werep repared (see the Experimental Section for their synthesis and the Supporting Information for chromatographic methods) and evaluated in terms of metabolic stability.F or this task, ac ombined approach based on microsomal and plasmatic stabilitya ssays was exploited considering the relevance of the plasmatic and hepatic tissues in esterase activity.M icrosomals tability of the selected esters was evaluated by monitoring the disappearance of the substrate incubatedi n rat liver microsomes (RLM) at 50 mm concentration, in the presence of NADPH. In Table 4 , the percentage of the remaining Figure 8 . Treatment with 64 prodrug inhibitedPI3K/Akt signaling. NIH3T3 cells were harvestedf or 12 hand were treatedw ith the indicatedconcentrations of 37 and 64.Cells were next stimulated with 1 mm insulin for 5min, and totalcell lysates were prepared. Immunoblot analysis was conducted for the expressionlevels of p-AKTand GAPDH. The immunoblot is representative of three independent experiments. substrate, after incubation (t = 60 min), with respect to the initial amount is reported. Overall, the compounds underwent a relevant metabolic transformation,a nd the substrate depletion ranged from 0( for 76)t o1 00 %( for 70). This is mainly due to hydrolysiso ft he ester function, whereas the metabolites arising from the oxidation catalyzed by the NADPH-dependent monooxygenase system weren egligible from aq uantitative point of view.I ndeed, the main metabolite formed during the incubation of the esters was corresponding carboxyl derivative 37.F urthermore, the addition of NADPH did not significantly increaset he oxidative metabolic transformation (see Figure S3 in Supporting Information). As expected, the aliphatic esters were found to be hydrolytically labile, and ethyl ester 67 was less stable than methyl ester 64, [22] whereas long, linear alkanoates 75 and 76 and branched esters 69 and 74 showed greaters tability. Moreover, whereas CH 2 -pyridin-4-yl ester 70 was completelym etabolized, corresponding benzyl derivative 65 and piperonyl derivative 72 weremore hydrolytically stable, and their residual substrates were 53 and 83 %, respectively. The hydrolytic stabilityo ft he selected esters was also evaluated by monitoring the depletion of the substrate incubated at a5 0 mm concentrationi nm ousep lasma over ap eriod of 30 min. As expected, the plasmatic metabolic fate of the esters was characterizedb yt he formation of 37 as the only metabolite (see Figure S4) . The rate constant k [min
À1
], derived for the substrate peak area versust ime curve (single-exponential decay equation-GraphPad Prism software, Inc.,S an Diego, CA (USA);s ee Figure S5 ) was used to calculate the in vitro half-life t 1/2 [min],a nd the valuesa re reported in Ta ble 4. Except for branched ester 69 and long, linear ester 76,w hich were inert to the mousep lasma hydrolases, the other compounds underwent relevant hydrolytic cleavage with t 1/2 values ranging from < 1t o1 5min. In detail, short-linear esters 67 and 73 in addition to benzyl derivative 65,C H 2 -pyridin-4-yld erivative 70,a nd piperonyl derivative 72 were rapidly hydrolyzed, and their t 1/2 valuesw ere less than 1min (see the Supporting Information).
The biological activity of each prodrug was tested by analyzing their ability to decrease PC3p roliferation as ar apid test to evaluatet he PI3Ks inhibitory activity after hydrolysis in ac ellbased assay.P C3 cells werei ncubated with 10 mm of each prodrug:c ompounds able to decreasep roliferation to an extent more than 50 %w ere defined as active, whereas those reducing to an extent less than 50 %w erec onsidered inactive. The choiceo fu sing such ac ut-off was due to the intent to identify rapidly which prodrug couldb eh ydrolyzed in the assay to release the active compound.A se xpected, ag ood correlation between rateo fh ydrolysis and cellular activity was observed, and esters 64-68 and 70-73 were determined to be good candidates for topicalu se. We decided to focus our attentiono n ester 64,a si ts half-life was ag ood compromise for ap rodrug. The EC 50 value of this ester wast hen evaluated on PC3 cells, and av alue of (2.3 AE 0.8) mm was obtained.
Conclusions
In conclusion, we report herein the discovery of 3-{[4-(2-morpholino-4-oxo-1,4-dihydroquinolin-8-yl)-1H-1,2,3-triazol-1-yl]methyl}benzoic acid (37), an ovel, potent pan-phosphoinositide 3-kinase (PI3K) inhibitort hat bears as trategic carboxylic acid, and the design of its ester prodrugs. Esterification of 37 generated molecules that were inactivei nt he enzymatic assay but that could cross cell membranes, and after ester hydrolysis, they inhibited the PI3Ks. To date, few prodrug PI3K inhibitors have been reported.O ne is ap rostate-cancer-specific PI3K inhibitor generated by coupling ac hemically modified form of the quercetin analogue LY294002 with the peptide Mu-LEHSSKLQL, in which the internal sequence HSSKLQi sasubstrate for the prostate-specific antigen protease. [23] The second prodrug was derived by conjugation of LY294002 to the amino terminus of the Arg-Gly-Asp-Ser integrin bindingt etrapeptide through am orpholinium methylsuccinate. [24] However,i nb oth prodrugs the biologically active portion was ablet oc ross cell membranes, which raises questions on side effects mediated by uncontrolleds ystemic inhibition of PI3Ks. Recently,A bbott et al. reported the generation of tetrazole analogues of LY294002 active on the a isoform of PI3K only if delivered as a prodrug. [25] Although different cancerc ell lines were used, an EC 50 value comparable with the one displayedb yo ur compound, methyl 3-{[4-(2-morpholino-4-oxo-1,4-dihydroquinolin-8-yl)-1H-1,2,3-triazol-1-yl]methyl}benzoate (64), was reported [EC 50 = (2.1 AE1.1) mm on MCF-7 versus (2.3 AE 0.8) mm on PC3].
Although pan-PI3K inhibitors are emerging as an ew opportunity in the treatment of non-cancer-related diseases,dataderived from clinicalt rials has demonstrated that treatmentw ith pan-PI3K inhibitors causes several side effects, including nausea,d iarrhea, rash, and increased released of insulin in plasma.T herefore, the unique properties of the prodrugs described in this manuscript might be considered of great relevance in the context of systemic toxicitym anagement. Indeed, these derivatives might explicatet heir activity exclusively within the cell, after conversion into 37,w hich might in turn decreases ystemic toxicity.T heirs hort half-lives,b oth in microsomes and plasma, highlight the therapeutic potential in topical administration (e.g.,a erosol therapy or epicutaneous treatment), which might overcome toxicitya nd avoid systemic exposure.I ndeed, severalp ieces of evidence suggest the use of pan-PI3K inhibitors in topicala dministration. [26, 27] Further studies are underway and will be performed to demonstrate the efficacy of compound 64 in different mousem odelso fc hronic inflammation, for which topical administration would be beneficial, such as asthma and psoriasis, and to evaluate its systemic toxicity.
Experimental Section
Generalprocedures
Commercially available reagents and solvents were purchased from Aldrich or Alfa Aesar and were used without further purification. Te trahydrofuran (THF) and toluene were distilled immediately before use from Na/benzophenone under as light positive atmosphere of dry nitrogen. Ethylenediamine was distilled immediately before use from CaH 2 under as light positive atmosphere of dry nitrogen. N,N'-Dimethylformamide (DMF) was distilled under vacuum from KOH and was stored on activated molecular sieves (4 ). Dichloromethane was dried by distillation from P 2 O 5 and was stored on activated molecular sieves (4 ) (25.0 g, 0.17 mmol) in DMSO (300 mL). The mixture was stirred for 3hat room temperature, and then iodomethane (2 equiv) was slowly added at 0 8C. The mixture was stirred overnight at room temperature. Ice was added to the flask to promote precipitation of the product, which was then filtered to yield compound 16 as ayellow solid (34.1 g, 81 %). 3-dioxane-4,6-dione (18) :Amixture of 5-[bis(methylthio)methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione (453 mg, 1.83 mmol) and 2-iodoaniline (400 mg, 1.83 mmol) in ethanol (4 mL) was heated at 80 8Cf or 4h.D uring the reaction, the product precipitated. Filtration yielded 18 as ayellow solid (522 mg, 68 %).
methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione (500 mg, 1.23 mmol) and morpholine (214 mL, 2.46 mmol) in THF (5 mL) was heated at reflux overnight. The volatiles were evaporated under reduced pressure. Diethyl ether (10 mL) was added, and the solid was filtered and washed with EtOAc (10 mL) to give 20 as awhite powder (429 mg, 76 %).
18 mmol) was heated in diphenyl ether (10 mL) at reflux for 30 min. The crude brown oil, after purification by column chromatography (petroleum ether/EtOAc 5:5t o0:1), yielded 21 as aw hite powder (519 mg, 67 %).
2-Morpholino-8-[(trimethylsilyl)ethynyl] quinolin-4(1H)-one (22):
Under an itrogen atmosphere, PdCl 2 (PPh 3 ) 2 (6 mg, 0.00843 mmol), Cu I (5 mg, 0.0252 mmol), DIPEA (48 mL, 0.280 mmol), and trimethylsilylacetylene (39 mL, 0.280 mmol) were added to as olution of 8-iodo-2-morpholinoquinolin-4(1H)-one (100 mg, 0.280 mmol) in toluene (2 mL) and DMF (two drops). The mixture was stirred at room temperature for 2h.T he mixture was diluted with water (10 mL) and extracted with EtOAc (5 10 mL). The combined organic layer was dried with sodium sulfate. The crude material was purified by column chromatography (EtOAc/MeOH 1:0t o95:5) to yield 22 as a yellow solid (66 mg, 72 %). (12):P otassium carbonate (949 mg, 6.88 mmol) was added to as olution of 2-morpholino-8-[(trimethylsilyl)ethynyl]quinolin-4(1H)-one (1.87 g, 5.74 mmol) in methanol (20 mL). The mixture was stirred at room temperature for 3h.T he volatiles were removed in vacuo. The mixture was diluted with brine (20 mL) and extracted with CH 2 Cl 2 (4 10 mL). The combined organic layer was dried with sodium sulfate. The crude material was purified by column chromatography (EtOAc/MeOH 1:0to9:1) to yield 12 as ay ellow solid (1.23 g, 84 %). [3,2,1-ij] quinolin-6(5H)-one (24):A lkyne 12 (78 mg, 0.31 mmol) was added to as uspension of phenyl azide (23;1 00 mg, 0.31 mmol) in water (570 mL) and tBuOH (570 mL). Then, 1 m aqueous sodium ascorbate (29 mL) and copper sulfate pentahydrate (0.72 mg, 0.29 mmol) were added under vigorous stirring. The product precipitated, and it was filtered and washed with water (2 5mL) and diethyl ether (2 5mL) to give 24 as a yellow solid (49 mg, 62 %).
8-Ethynyl-2-morpholinoquinolin-4(1H)-one
4-Morpholino-4H-pyrrolo
General procedure for the synthesis of compounds 25-54:T BTA (0.0040 mmol, 0.05 equiv) was added to as olution of Cu(OAc) 2 (0.0040 mmol, 0.05 equiv) in THF (0.3 mL), and the resulting mixture was stirred at room temperature for 30 min. As olution of azide 13 (0.079 mmol, 1equiv) in THF (0.3 mL), as olution of alkyne 12 (0.079 mmol, 1equiv) in THF (0.3 mL), and as olution of sodium ascorbate (0.0079 mmol, 0.1 equiv) in am inimum amount of water were added. The mixture was stirred at room temperature overnight. The product precipitated, and it was filtered and washed with water (2 5mL) and diethyl ether (2 5mL) to give as olid. The crude product was then screened, and compounds 25, 35, 37, ChemMedChem 2017 25, 35, 37, ChemMedChem , 12,1542 25, 35, 37, ChemMedChem -1554 www.chemmedchem.org 2017 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim 45, 48,a nd 54 were resynthesized and subjected to column chromatography (EtOAc and EtOAc/MeOH 9:1). (25) 7, 152.8, 137.3, 136.4, 131.1, 130.6 (2C), 129.2, 128.7, 126.3, 124.3, 121.9, 121.7, 120.6, 91.8, 66.5, 46.4 (27) :Y ellow solid (40 %). 8, 138.4, 134.5, 133.8, 132.6 (2 C), 131.5, 128.7, 123.1, 121.6, 121.2, 115.2, 113.6, 112.5, 110.9, 106.0, 92.1, 66.5, 56.1, 45.7 ppm; I R (KBr): ñ = 3263, 2965 I R (KBr): ñ = 3263, , 1622 I R (KBr): ñ = 3263, , 1583 I R (KBr): ñ = 3263, , 1495 I R (KBr): ñ = 3263, , 1235 I R (KBr): ñ = 3263, , 1123 I R (KBr): ñ = 3263, , 1003 = 7.7 Hz, 1H), 7.93 (d, J = 3.3 Hz, 1H), 7.88 (d, J = 7.7 Hz, 1H), 7.51 (t, J = 7.7 Hz, 1H), 2H), 7.02 (d, J = 3.3 Hz, 1H), 6.50 (s, 1H), 5.75 (s, 2H), 4H), 4H); 13 CNMR (75 MHz, [D 6 ]DMSO): d = 162. 4, 159.6, 145.1, 136.2, 134.5, 133.6, 133.1, 130.2, 130.0, 128.2, 126.0, 125.6, 125.2, 122.3, 121.5, 121.2, 118.3, 91.9, 66.5, 53.2, 45.8 ppm; I R( KBr): ñ = 2970 I R( KBr): ñ = , 2866 I R( KBr): ñ = , 1707 I R( KBr): ñ = , 1636 I R( KBr): ñ = , 1582 I R( KBr): ñ = , 1444 I R( KBr): ñ = , 1242 I R( KBr): ñ = , 1117 C6 4.03, H4.91, N1 6.23; f ound:C64.00, H4 .98, 2, 6.9 Hz, 2H), 2H), 7.97 (d, J = 6.9 Hz, 2H), 7.33 (t, J = 8.2 Hz, 1H), 6.54 (s, 1H), 4H), 4H); 13 CNMR (75 MHz, [D 6 ]DMSO): d = 161. 3, 159.8, 138.2, 136.2, 133.3, 132.6, 131.7, 131.4, 128.7, 126.4, 124.1, 123.8, 121.2, 120.6, 111.8, 92.0, 66.3, 46.3 ppm; I R( KBr): ñ = 3336, 3128, 1697 I R( KBr): ñ = 3336, 3128, , 1620 I R( KBr): ñ = 3336, 3128, , 1585 I R( KBr): ñ = 3336, 3128, , 1414 I R( KBr): ñ = 3336, 3128, , 1238 8.03 (d, J = 7.7 Hz, 1H), 7.83 (d, J = 7.7 Hz, 1H), 5H), 7.24 (t, J = 7.7 Hz, 1H), 5.81 (s, 1H), 5.68 (s, 2H), 4H), 4H); 13 CNMR (75 MHz, [D 6 ]DMSO): d = 160. 2, 145.2, 136.5, 131.8, 130.4, 129.4, 129.0, 128.2, 127.4, 127.3, 125.1, 122.3, 121.6, 118.6, 91.9, 66.5, 53.6, 45.8 ppm; I R( KBr): ñ = 3264, 3142, 1628 I R( KBr): ñ = 3264, 3142, , 1586 I R( KBr): ñ = 3264, 3142, , 1501 I R( KBr): ñ = 3264, 3142, , 1445 I R( KBr): ñ = 3264, 3142, , 1255 I R( KBr): ñ = 3264, 3142, , 1117 C6 8.20, H5 .46, N 18.08; found:C68.18, H5 .72, N1 7.83. (d, J = 7.7 Hz, 1H), 7.00 (t, J = 7.7 Hz, 1H), 6.55 (s, 1H), 4H), 4H); 13 CNMR (75 MHz, [D 6 ]DMSO): d = 159. 5, 154.8, 149.4, 145.2, 141.3, 130.1, 128.3, 127.0, 126.0, 125.2, 124.7, 121.6, 120.3, 117.9, 109.9, 101.3, 92.0, 66.6, 51.9 ppm; I R (KBr): ñ = 3230, 2949 I R (KBr): ñ = 3230, , 1632 I R (KBr): ñ = 3230, , 1586 I R (KBr): ñ = 3230, , 1236 I R (KBr): ñ = 3230, , 1123 
+ ;e lemental analysis calcd (%) for C 21 H 19 N 5 O 3 (389.41): C6 4.77, H4 .92, N1 7.98; f ound:C64.88, H 5.17, (24 %) . 2 mL) . The mixture was stirred at 110 8Co vernight. Diethyl ether (3 mL) was added to the mixture, and the product precipitated. It was filtered to yield 63 as ab rown solid (214 mg, 98 %).
General procedure for the synthesis of ester prodrugs 64-76: TBTA( 0.0040 mmol, 0.05 equiv) was added to as olution of Cu(OAc) 2 (0.0040 mmol, 0.05 equiv) in THF (0.3 mL), and the resulting mixture was stirred at room temperature for 30 min. As olution of the azide (0.079 mmol, 1equiv) in THF (0.3 mL), as olution of alkyne 12 (0.079 mmol, 1equiv) in THF (0.3 mL), and as olution of sodium ascorbate (0.0079 mmol, 0.1 equiv) in am inimum amount of water were added. The mixture was stirred at room temperature overnight. The product precipitated, and it was filtered and washed with water (2 5mL) and diethyl ether (2 5mL) to give a solid. The crude product was subjected to column chromatography (EtOAc and EtOAc/MeOH 9:1). bis N, N', dimethylammonio]-1-propanesulfonate}. In the reaction, the ATPc oncentration used for different PI3Ks was defined on the basis of the Michaelis-Menten kinetics of each enzyme, provided by the supplier.R eaction was performed in presence of 0.5 mg mL À1 lipid micelles (1:1 phosphatidylinositol/phosphatidylserine) and in the absence (DMSO alone) or presence of increasing concentrations of each compound (from 0.1 nm to 30 mm). The mixture was kept at room temperature (RT) for 30 min for PI3Ka,P I3Kb,P I3Kg,P I3Kd,P I3KC-2a,a nd PI3KC-2g and for 1h for PI3K-C2b and PI3K-C3. The amount of ADP produced in the reaction was measured by using the ADP-Glo Kinase Assay kit from Promega (#V9102) and aluminescence reader (Glomax multi detection system, Promega, model number 9301-010).
The residual PI3K lipid kinase activity in the presence of each molecule at different concentrations was related to the control, intended as the recombinant protein in the presence of DMSO alone and was expressed as ap ercentage. To derive the IC 50 value, all data (% of lipid kinase activity) were plotted on ad ose-response curve (Graph Pad software), and the IC 50 was calculated by using nonlinear regression fit (equation [log agonist] versus response).
Lineweaver-Burk plot:T he linear phase of the kinetic reaction was defined with 2.4 mgmL À1 of PI3Kd in a2 0min reaction time. In the presence of increasing concentrations of 37 (5, 10 and 20 nm) , the PI3K lipid kinase activity (for the assay method see "In vitro selection, lipid kinase assay" in the Experimental Section) was assayed at various concentrations of ATP ( 5, 10, 25, 50 , and 100 mm)a nd in the presence of 0.5 mg mL penicillin-streptomycin (Gibco). Subsequently,P C3 cells were incubated with increasing concentrations of 68 for 12 h. Cells were then lysed with al ysis buffer containing 20 mm Tris-HCl pH 8, 138 mm NaCl, 2.7 mm KCl, 1mm CaCl 2 ,5m m EDTAp H8,1m m MgCl 2 ,5%g lycerol, 1% Triton X-100, and protein extracts were analyzed by Western blot analysis. To assess the phosphorylation level of proteins involved in the PI3K/Akt signaling pathway,t he following antibodies were used: phospho-Akt (Ser473) (#4060 Cell Signaling Te chnology,U SA), phospho-Akt (Ser308) (#13038 Cell Signaling Technology,U SA), Akt1 (#2967 Cell Signaling Technology,U SA), phospho-PRAS40 (Thr246) (#2640 Cell Signaling Technology,U SA), PRAS40 (#2610 Cell Signaling Te chnology,U SA), Phospho-p70 S6 Kinase (Thr389) (Cell Signaling Te chnology #9205), Phospho-GSK-3a/b (Ser21/9) (Cell Signaling Technology #8566), GSK-3a/b Cell Signaling Technology #5676), phospho-FoxO1 (Thr24)/FoxO3a (Thr32) (Cell Signaling Te chnology #9464), FoxO3a (Cell Signaling Te chnology #2497), GAPDH (8C2) (Santa Cruz sc-81545), and p70 S6 kinase a (H-160) (Santa Cruz sc-9027).
NIH3T3 cells were seeded in a9 6-well plate and starved overnight (ON) with serum-free DMEM high glucose GlutaMAXTM (Gibco) supplemented with 5000 UmL À1 penicillin-streptomycin (Gibco). Cells were then incubated for 1hwith increasing concentrations of 64, 37,o rD MSO. Subsequently,c ells were stimulated for 5min with 1 mm of insulin (#91077C, Sigma-Aldrich, USA). Cells were lysed and protein extracts were analyzed by western blot to assess the phosphorylation level of Akt on Ser473.
Cell proliferation:P C3 cell proliferation was measured with a3 -(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-based colorimetric assay (#114 65 007 001 Roche Diagnostic GmbH, Germany). PC3 cells were seeded in a9 6-well plate at ac oncentration of 10 4 cells mL
À1
.P C3 cells were treated for 72 hw ith increasing concentrations of 64,a nd MTT was added. After ON solubilization of the MTT metabolite, formazan, the absorbance (l = 550-600 nm absorbance, with ar eference wavelength of 650 nm) of each well was read in am ulti-well reader (Glomax multi detection system, Promega, model number 9301-010). The percentage of proliferating cells was calculated by relating each absolute value to the control intended as PC3 cells treated with DMSO alone. An IC 50 value was then derived by plotting all data on ad ose-response curve (Graph Pad software) by using nonlinear regression fit (equation [log agonist] versus response).
Cell-cycle analysis:F or DNA content determination, PC3 cells were seeded at 4 10 5 cells per 6cmd ish in triplicate in the presence of DMEM high glucose GlutaMAXTM (Gibco), 10 %f etal bovine serum (Invitrogen) supplemented with 5000 UmL À1 penicillin-streptomycin (Gibco). The day after seeding, cells were treated for 48 hw ith 10 mm 64 or DMSO. Subsequently,P C3 cells were detached with 0.1 %t rypsin-EDTA( Gibco), fixed in 70 %e thanol overnight at À20 8C, and stained for 40 min at 57 8Cw ith PI solution, containing 0.05 %T riton X-100, 0.1 mg mL À1 RNase, and 25 mgmL À1 propidium iodide. Sample were analyzed for the DNA content by using a FACS-Calibur flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, USA). The percentages of cells in the G0/G1, S, and G2 phases were calculated.
Analysis of apoptosis:F or Annexin Vs taining of apoptotic cells, PC3 cells were seeded at 4 10 5 cells per 6cmd ish in triplicate. Cells were incubated 48 hi nt he presence or absence of 10 mm 64 and were then detached with 0.1 %t rypsin-EDTA, resuspended in Annexin buffer (10 mm HEPES, pH 7.4, 140 mm NaCl, 2.5 mm CaCl 2 ), and stained for Annexin V( FITC Annexin V# 640906, BioLegend, USA). Samples were analyzed by using aF ACS-Calibur flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, USA).
Additional biological experiments, crystallographic details, the pdb file for the X-ray crystal structure of 5NGB, and metabolism stability studies are available in the Supporting Information.
